The cure STARTs here.
START is dedicated to the conduct of Phase I Clinical Trials of novel
anticancer agents.
The mission of START is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START operates under the leadership of Dr. Anthony W. Tolcher, Dr. Amita Patnaik and Dr. Kyriakos P. Papadopoulos and consists of a team of highly trained staff with extensive experience in Phase I clinical trials research.
Clinical Research
New Hope for Patients. . . New Hope for a Cure
With centers located in San Antonio, Texas and Madrid, Spain, START conducts the world’s largest Phase I medical oncology program. Today, more than 50 percent of cancer patients can be cured with conventional treatments – that is, therapies with a proven response rate. However, there are many patients who do not respond to standard treatment and may be eligible for participation in our Phase I clinical trials program.
Preclinical Research
START is dedicated to developing improved preclinical models and assays to accelerate oncology drug development.
START's preclinical program is unique in that our researchers work alongside leading Phase I clinicians whose clinical experience and collaboration allows us to accelerate the movement of agents through preclinical development and into first in man studies.
START Madrid
In 2008 START expanded globally with the opening of START Madrid. This International program is the first step in our goal to keep the development of anticancer agents operating 24 hours a day. Because of the work of scientists like those at START and START Madrid, real progress is being made against cancer.
Lastest News
February 13th, 2012 START Center begins groundbreaking genome study
November 14th, 2011 START Madrid Receives Spain’s first Accreditation of Excellence Awarded to a Phase I Unit
